- Home
- PBYI vs IAF Comparison
PBYI vs IAF Comparison
Compare PBYI & IAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- IAF
- Stock Information
- Founded
- PBYI 2010
- IAF 1985
- Country
- PBYI United States
- IAF United States
- Employees
- PBYI N/A
- IAF N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- IAF Finance/Investors Services
- Sector
- PBYI Health Care
- IAF Finance
- Exchange
- PBYI Nasdaq
- IAF Nasdaq
- Market Cap
- PBYI 167.3M
- IAF 103.9M
- IPO Year
- PBYI N/A
- IAF N/A
- Fundamental
- Price
- PBYI $3.38
- IAF $4.45
- Analyst Decision
- PBYI Strong Buy
- IAF
- Analyst Count
- PBYI 1
- IAF 0
- Target Price
- PBYI $7.00
- IAF N/A
- AVG Volume (30 Days)
- PBYI 379.0K
- IAF 90.4K
- Earning Date
- PBYI 07-31-2025
- IAF 01-01-0001
- Dividend Yield
- PBYI N/A
- IAF 11.44%
- EPS Growth
- PBYI 143.51
- IAF N/A
- EPS
- PBYI 0.77
- IAF N/A
- Revenue
- PBYI $232,709,000.00
- IAF N/A
- Revenue This Year
- PBYI N/A
- IAF N/A
- Revenue Next Year
- PBYI N/A
- IAF N/A
- P/E Ratio
- PBYI $4.36
- IAF N/A
- Revenue Growth
- PBYI 2.68
- IAF N/A
- 52 Week Low
- PBYI $2.23
- IAF $3.60
- 52 Week High
- PBYI $4.13
- IAF $4.59
- Technical
- Relative Strength Index (RSI)
- PBYI 48.53
- IAF 60.01
- Support Level
- PBYI $3.25
- IAF $4.35
- Resistance Level
- PBYI $3.39
- IAF $4.48
- Average True Range (ATR)
- PBYI 0.15
- IAF 0.07
- MACD
- PBYI -0.03
- IAF -0.01
- Stochastic Oscillator
- PBYI 22.22
- IAF 72.22
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About IAF abrdn Australia Equity Fund Inc.
Aberdeen Australia Equity Fund Inc is a non-diversified closed-end investment management company. With a core focus on long-term capital appreciation, it invests predominantly in equity securities listed on the Australian Stock Exchange. Its secondary objective is current income, which it expects to derive from dividends and interest on Australian corporate and governmental securities. Its investment portfolio comprises diversified sectors that include Financials, Health Care, Materials, Information Technology, Real Estate, and other sectors.